Mon, 14th Jun 2010 12:22
LONDON (Alliance News) - Akers Biosciences Inc said Wednesday that it had inked a sales and distribution agreement with Typenex Medical LLC for its PIFA Heparin/PF4 and PIFA PLUSS Platelet Factor 4 test kits. Akers said that the agreement was part of its strategy to accelerate sales of the
Read moreAkers Biosciences, which manufactures rapid diagnostic screening and testing products, has entered into a sales and distribution agreement with US-based Typenex Medical, a product development and sales organisation. Under the contract, which can be renewed after one year by mutual consent, the gro
Read moreLONDON (Alliance News) - UK shares have opened mostly lower, with small-caps slightly outperforming Wednesday ahead of the Queen's Speech and further European economic data.
Starting the trading day on a negative note, Tesco PLC reported a sharp drop in sales in the
LONDON (Alliance News) - Akers Biosciences Inc said Friday that it had inked an agreement with Nevada-based Jai Capital LLC to market its rapid test products in India. Under the agreement Jai will market Aker's PIFA Heparin/Platelet Factor-4 Rapid Assay test for thrombosis, its PIFA Dengue
Read moreAIM-listed healthcare equipment firm Akers Biosciences has entered into an agreement with medical devices market developer Jai Capital to launch the group's PIFA Heparin/Platele in India. The Nevada-based group will market the company's product to the Indian military, which is allowed to buy produc
Read moreLONDON (Alliance News) - Akers Biosciences Inc, which recently listed on Nasdaq, Wednesday reported a first-quarter net loss of USD595,600, mainly due to the costs of the initial public offering. The maker of rapid diagnostic screening and testing products, which is also listed on London's
Read moreLONDON (Alliance News) - Akers Biosciences Inc Wednesday said it had signed a deal whereby Dubai-based Thirty Six Strategies General Trading LLC will sell Akers' infectious diseases tests exclusively for the next three years in some countries. In a statement, Akers said the exclusive agreem
Read moreAIM- and Nasdaq-listed healthcare equipment firm Akers Biosciences has signed a three-year distribution agreement to sell its products in Australia, Singapore, the United Arab Emirates and Oman. Dubai-based procurement company, 36S, will immediately begin marketing Aker's PIFA PLUSS infectious dis
Read moreLONDON (Alliance News) - Akers Biosciences Inc said Wednesday that it has begun clinical trials in the US for its PIFA PLUSS chlamydia assay, a test for chlamydia diagnosis using a finger stick blood sample. The study will include 200 to 250 patients in total, including normal, newly infect
Read moreLONDON (Alliance News) - Akers Biosciences Inc Friday posted a narrowed pretax loss for 2013, as it saw revenues more than double, driven by sales of its breathalyser products, and expressed confidence for 2014 following its dual listing in New York in January. The company posted a pretax l
Read moreLONDON (Alliance News) Akers Biosciences Wednesday said Chief Executive Thomas Nicolette will step down from the board and leave the company on March 28. Nicolette, who has been at the helm since 2008, will be replaced by Executive Chairman Raymond Akers. The stock closed at 340.00 pe
Read moreLONDON (Alliance News) - Bank of England Governor Mark Carney Friday signaled that rising productivity will now be the key factor that decides when the central bank will start to tighten monetary policy, and any tightening will be a slow, gradual process.
In a speech at the World Ec
LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Friday. ------- FTSE 100 - WINNERS Weir Group, up 0.2%. The engineering company said it had won a USD98 million, or GBP59 million, two-year contract to provide
Read more